Liverpool Ocular Oncology<br />Research Group
 
  • HOME
  • NEWS
  • Research Team
  • Disease Focus and Research
    • Uveal Melanoma
    • Conjunctival melanoma
    • Ocular Adnexal Lymphoma
  • Molecular Pathology
  • Ocular Oncology Biobank (OOB)
  • Paper Publications
    • 2025
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
    • 2005
    • 2004
  • Book Chapters
  • Informative Videos
  • Alumni
    • Previous Staff
    • Past PhD Students
    • Past MD Students
    • Past MRes Students
    • Past BSc/MSc Students
    • Nuffield Students
  • Visitors
    • Visiting researchers and clinicians
    • Visiting Students
    • Patients & Public
  • Support Us/Donations
  • Fundraising Events
  • Training and Opportunities
  • Contact us
  • Links

Multicenter External Validation of the Liverpool Uveal Melanoma Prognosticator Online: An OOG Collaborative Study

20/2/2020

 
Picture
Abstract:
Uveal melanoma (UM) is fatal in ~50% of patients as a result of disseminated disease. This study aims to externally validate the Liverpool Uveal Melanoma Prognosticator Online V3 (LUMPO3) to determine its reliability in predicting survival after treatment for choroidal melanoma when utilizing external data from other ocular oncology centers. Anonymized data of 1836 UM patients from seven international ocular oncology centers were analyzed with LUMPO3 to predict the 10-year survival for each patient in each external dataset. The analysts were masked to the patient outcomes. Model predictions were sent to an independent statistician to evaluate LUMPO3’s performance using discrimination and calibration methods. LUMPO3’s ability to discriminate between UM patients who died of metastatic UM and those who were still alive was fair-to-good, with C-statistics ranging from 0.64 to 0.85 at year 1. The pooled estimate for all external centers was 0.72 (95% confidence interval: 0.68 to 0.75). Agreement between observed and predicted survival probabilities was generally good given differences in case mix and survival rates between different centers. Despite the differences between the international cohorts of patients with primary UM, LUMPO3 is a valuable tool for predicting all-cause mortality in this disease when using data from external centers.  See full article bit.ly/37MRMCe
First author - Dr Alda Cunha Rola (picture)


Comments are closed.
Powered by Create your own unique website with customizable templates.